Oncology Experts

Manuel Hidalgo-medina

Professor of Medicine
Beth Israel Deaconess Medical Center
United States of America


Manuel Hidalgo-Medina, M.D., is a Professor of Medicine at Beth Israel Deaconess Medical Center in Boston. He went to medical school at Universidad de Navarra and completed his residency at Hospital Doce de Octubre, with a fellowship at University of Texas Health Science Center.

Research Interest

Medical Oncology


  • Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. Journal of Clinical Oncology. 2016 Nov 21;35(2):157-65.

  • Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A. A Phase Ib Doseā€Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. The Oncologist. 2017 Jun 7:theoncologist-2017.

  • Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan RJ, Arance A, Kefford RF, Carlino MS. Phase I Dose-Escalation and-Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Clinical Cancer Research. 2017 Jan 1:clincanres-2923.

Global Experts from United States of America

Global Experts in Subject

Share This Profile
Recommended Conferences